Business Wire

Toshiba at EuroCIS: Empowering Retailers to “Create Your Tomorrow”

13.2.2025 09:00:00 CET | Business Wire | Press release

Share

Attendees will experience solutions for secure, seamless, and personalized shopping

At EuroCIS 2025, Toshiba Global Commerce Solutions showcases how it empowers retailers with its innovative solutions portfolio for smart stores, customer personalization, and security (booth in hall 9 #B42). The international trade fair will take place on February 18-20 in Düsseldorf, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213535650/en/

The new TCx 820 all-in-one POS system is suitable for all types of store environments as it is available in various formats and screen sizes. (Photo: Business Wire)

“In a world brimming with possibilities, every retailer can shape their own future and deliver exceptional customer experiences and growth with the help of an experienced partner,” says Robin Lyon, Executive Director of Channels & Marketing, Toshiba Global Commerce Solutions. “To empower retailers to create their own tomorrow, Toshiba delivers complete solutions comprising of its modular MxP® hardware, software and services harnessing the power of AI, computer vision, and other transformative technologies. Advanced self-service solutions and new POS technologies are designed to meet the unique needs of retailers, no matter their size or segment.”

Innovative Solutions shown on the Toshiba booth

  • Loss prevention and customer experience at self-checkout: The new Modular eXpansion Platform (MxP®) provides self-checkout solutions in a sleek design tailored for all retail segments. Various form factors feature capabilities for loss prevention and produce recognition using AI, computer vision and IoT sensors to recognize shrinkage and speed up transactions. Toshiba’s TCx® EDGEcam+ cameras monitor customer behaviors without in-store servers, enhancing security throughout the checkout area. For fast scan-free self-checkout, the MxP® VisionKiosk uses computer vision and AI to automatically identify items for a seamless shopping experience.
  • Flexible POS-systems and versatile Touch Displays: The new TCx® 820 all-in-one POS-system and TCx® Touch Displays are available in multiple formats with a sleek design ready for all retail segments. They are configurable in five formats enabling seamless integration into any retail environment or use case. Screen sizes range from 10” to 24” with both landscape and portrait orientations available.
  • Personalized shopping experiences: Catch Retail is an AI retail media platform for physical spaces, monetizing first-party data for retailers and brands, enabling them to reach new, targeted audiences in stores. Catch will demonstrate how they are revolutionizing in-store customer engagement, brand loyalty and revenue growth by enabling personalized media through various shopping touchpoints.
  • AI-powered refrigeration management: Axiom Cloud will demonstrate how retailers can reduce energy consumption and save on maintenance costs in their cold chain operations using AI.
  • Toshiba Commerce Marketplace: Aimed at meeting the ever-evolving needs of retail, the Toshiba Commerce Marketplace enables retailers to connect to an extensive network of industry-leading technology partners and solutions to stay competitive in an increasingly digital world, to enhancebusiness operations, and improve the shopping experience. Today, the Commerce Marketplace includes partners such as Adyen, Zebra, Datalogic, Ingenico, Ecrebo, Qualcomm, Honeywell, and Aptos, amongst others.

Toshiba will speak on the Blue and Red Stages

Toshiba experts will also share their knowledge and expertise on the EuroCIS stages:

February 18 at 11:40 - 12:00 on the Blue Stage (hall 10 G65)

The Business Benefits of Switching to a Secure Retail Cloud
Johnny Flynn, Retail Cloud Architect, Toshiba Global Commerce Solutions

February 19 at 14:00 - 14:20 on the Red Stage (hall 10 G01)

From Simple Break-Fix Maintenance to Sustainable Business Availability Management
Catherine Bataille, Director Professional Services, Toshiba Global Commerce Solutions
Dries de Beul, Technical Design & Solution Architect, Toshiba Global Commerce Solutions

To arrange to meet with Toshiba at EuroCIS, follow this link: Book a Meeting with Toshiba

About Toshiba Global Commerce Solutions:

Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs.

Visit commerce.toshiba.com and engage with us on:
LinkedIn - YouTube - Facebook - Instagram: @toshibacommerce
X/Twitter: @ToshibaCommerce

Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250213535650/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye